ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Non-Human Primates: The Immunomodulatory Effect of Donor Bone Marrow Transplantation Does Not Prevent the Development of Chronic Rejection in the Absence of Durable Mixed Chimerism.

Z. Ng, A. Lellouch, A.-R. Gama, I. Schol, I. Rosales, R. Colvin, L. Geoghegan, J. Kurtz, C. Cetrulo.

Massachusetts General Hospital, Boston, MA

Meeting: 2017 American Transplant Congress

Abstract number: 99

Keywords: Alloantibodies, Engraftment, Graft failure, Skin transplantation

Session Information

Session Name: Concurrent Session: VCA

Session Type: Concurrent Session

Date: Sunday, April 30, 2017

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:06pm-3:18pm

Location: E270

PURPOSE: Donor bone marrow transplantation (DBMT) has been investigated in experimental and clinical vascularized composite allotransplantation (VCA). With longer-term follow-up, reports of chronic VCA rejection have emerged. We investigated the immunomodulatory effect of DBMT on chronic VCA rejection in non-human primates (NHPs).

METHODS: Following VCA and maintenance on conventional immunosuppression (IS) for 2 months, DBMT was performed in MHC-mismatched NHPs (n=6) after non-myeloablative recipient conditioning. A 4-week course of calcineurin inhibition (CNI) was then given before IS withdrawal and assessment for VCA tolerance. Observed rejection episodes were biopsied, treated with CNI and a tapering course of steroids before complete withdrawal after 2 weeks. Systemic immune function was assessed with CFSE-MLR; allo-antibody and chimerism detection was based on flow cytometry.

RESULTS: In the absence of durable mixed chimerism, DBMT allowed IS-free survival for 4-5 weeks before Banff II acute rejection developed (POD115-126). While rejection could be treated and reversed both clinically and histologically, following re-withdrawal of IS, Banff II rejection recurred within 2 weeks (POD172). Despite treatment, rejection could not be reversed (Banff II, POD195) and ultimately culminated in VCA necrosis (POD224). Final histology showed severe ACR and AMR with C4d deposition in subcutaneous arteries and arterioles and chronic vasculopathy (Figure 1). Corresponding serial MLR demonstrated donor-unresponsiveness after DBMT and absence of allo-antibodies.

CONCLUSIONS: While DBMT demonstrated systemic immunomodulation based on MLR, in the absence of durable mixed chimerism, acute and ultimately chronic rejection could not be averted. The presence of vascular lesions (based on C4d deposition) following DBMT may predate clinical progression to eventual chronic rejection and represent a potential prognostic factor in clinical VCA.

CITATION INFORMATION: Ng Z, Lellouch A, Gama A.-R, Schol I, Rosales I, Colvin R, Geoghegan L, Kurtz J, Cetrulo C. Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Non-Human Primates: The Immunomodulatory Effect of Donor Bone Marrow Transplantation Does Not Prevent the Development of Chronic Rejection in the Absence of Durable Mixed Chimerism. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ng Z, Lellouch A, Gama A-R, Schol I, Rosales I, Colvin R, Geoghegan L, Kurtz J, Cetrulo C. Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Non-Human Primates: The Immunomodulatory Effect of Donor Bone Marrow Transplantation Does Not Prevent the Development of Chronic Rejection in the Absence of Durable Mixed Chimerism. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/delayed-tolerance-induction-protocol-for-vascularized-composite-allografts-in-non-human-primates-the-immunomodulatory-effect-of-donor-bone-marrow-transplantation-does-not-prevent-the-development-of-c/. Accessed May 12, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences